Core Viewpoint - Exelixis anticipates significant clinical, regulatory, and commercial progress in 2026, focusing on expanding its cabozantinib business and developing zanzalintinib as a potential second commercial franchise while advancing its earlier-stage pipeline [1][19]. Financial Results and Guidance - Preliminary total revenues for fiscal year 2025 are approximately $2.320 billion, with guidance for fiscal year 2026 set between $2.525 billion and $2.625 billion [3]. - Net product revenues for fiscal year 2025 are approximately $2.123 billion, with guidance for fiscal year 2026 ranging from $2.325 billion to $2.425 billion [3]. - Cost of goods sold as a percentage of net product revenues is approximately 3.7% for 2025, with a projected range of 3.5% to 4.5% for 2026 [3]. - Research and development expenses for 2025 are approximately $825 million, with guidance for 2026 set between $875 million and $925 million [3]. - Selling, general, and administrative expenses for 2025 are approximately $520 million, with guidance for 2026 ranging from $575 million to $625 million [3]. - The effective tax rate for 2026 is projected to be between 21% and 23% [3]. Business Updates - The company is focused on leveraging its diverse pipeline and key clinical collaborations to build next-generation oncology franchises aimed at improving cancer care standards [1][6]. - Exelixis expects continued growth in its cabozantinib franchise, which is the leading tyrosine kinase inhibitor in renal cell carcinoma and neuroendocrine tumors [7]. - The company achieved major milestones with zanzalintinib, including a positive pivotal data readout and a U.S. regulatory filing for its use in metastatic colorectal cancer [6][8]. Regulatory and Clinical Milestones - The FDA is currently reviewing Exelixis' New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer [2][8]. - The STELLAR-303 trial for zanzalintinib has shown a statistically significant reduction in the risk of death compared to regorafenib, with further analyses expected in mid-2026 [8][9]. - The STELLAR-304 trial is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated advanced non-clear cell renal cell carcinoma, with results anticipated in mid-2026 [10]. Pipeline Development - Exelixis is advancing several phase 1 clinical trials for new molecules, including XL309, XB010, XB628, and XB371, with plans to progress them into full development if data are supportive [12]. - The company anticipates initiating two new IND applications in 2026, further expanding its oncology pipeline [13]. Stock Repurchase Program - Exelixis has repurchased a total of $2.16 billion of its common stock since March 2023, with an additional $750 million authorized for repurchase before December 31, 2026 [15].

Exelixis (EXEL) Conference Summary Company Overview - Exelixis is a cancer-focused commercial company dedicated to improving cancer treatment standards for patients, with a leading molecule in kidney cancer called CABOMETYX (cabozantinib) [2][3] Key Points Product Development and Pipeline - CABOMETYX has shown strong commercial performance and has been incrementally growing with new indications over time [4][16] - The company aims to build a pipeline of franchise molecules beyond CABOMETYX, including Zanzalutinib, which is currently in pivotal trials [2][17] - The company has a deep pipeline of both small molecules and biologics [2][17] Financial Performance - Exelixis issued guidance for net product revenue between $2.25 billion and $2.35 billion for the year, primarily driven by renal cell carcinoma (RCC) [19] - The company raised its midpoint guidance from $2 billion to $2.1 billion due to strong first-quarter performance [19][20] - Revenues have tripled over the last four to five years, attributed to strong data and effective physician education [15][16] Market Share and Growth Potential - CABOMETYX has a 25% market share in the first-line RCC setting and over 45% in the second-line setting, indicating room for growth [23][24] - The company has been growing market share quarter over quarter, with a notable 4-point increase in market share from Q2 2024 to Q2 2025 [20] New Indications and Collaborations - The company launched a new indication for NET (neuroendocrine tumors) in Q2 2025, with significant market potential estimated at around $1 billion [28][30] - The collaboration with academic institutions has been crucial for running pivotal trials, leading to successful outcomes [28][29] Zanzalutinib Development - Zanzalutinib is designed to mimic CABOMETYX's inhibitory activity but with a shorter half-life, facilitating easier dose adjustments [44][46] - Positive data from pivotal trials in colorectal cancer and other indications have been reported, with expectations for further data releases [47][50] Challenges and Strategic Focus - The company faces competition from larger pharmaceutical companies in the RCC space, necessitating a strong focus on data quality and physician education [21][22] - Exelixis is prioritizing building franchises around successful indications and molecules, with a focus on less competitive areas like colorectal cancer and meningioma [57][58] Future Outlook - The company is optimistic about the potential for Zanzalutinib and other pipeline products to enhance its market position without cannibalizing existing products [66][67] - Exelixis emphasizes the importance of improving patient outcomes as the primary measure of success, guiding its strategic decisions [71][72] Additional Insights - The company has navigated challenges such as the COVID-19 pandemic while maintaining focus on its goals [16] - The management is committed to continuous improvement in cancer treatment standards, which is central to its operational philosophy [71][72]